Scott Haden Kollins
Professor in Psychiatry and Behavioral Sciences
Education & Training
Ph.D., Auburn University 1997
Scott H. Kollins, PhD received his undergraduate degree in psychology from Duke and his Master’s and Doctorate degrees in Clinical Psychology from Auburn University. After completing his clinical internship at the University of Mississippi Medical Center, where he served as Chief Intern, he joined the faculty of the Department of Psychology at Western Michigan University for three years, before joining the Duke faculty in 2000. Dr. Kollins has published more than 125 scientific papers in peer-reviewed journals. Over the past 10 years, his research has been supported by 6 different federal agencies, including NICHD, NIDA, NIMH, NIEHS, NINDS, and EPA, and he currently holds a mid-career K24 award from NIDA. He has also served as PI on more than 40 industry-funded clinical trials and is a consultant to a number of pharmaceutical companies in the area of ADHD clinical psychopharmacology. He has served as a standing member of the Child Psychopathology and Developmental Disabilities study section and also served as an ad-hoc reviewer for 10 additional NIH study sections and 7 international granting agencies. He is an Associate Editor for the Journal of Attention Disorders and has reviewed for more than 50 different peer-reviewed journals. He is an elected member of the College on Problems of Drug Dependence and the American College of Neuropsychopharmacology. Dr. Kollins is a licensed clinical psychologist and maintains a practice through the ADHD Program’s outpatient clinic. His research interests are in the areas of psychopharmacology and the intersection of ADHD and substance abuse, particularly cigarette smoking.
Schechter, JC, and Kollins, SH. "Prenatal Smoke Exposure and ADHD: Advancing the Field." Pediatrics 139.2 (February 2017). Full Text
Childress, AC, Kollins, SH, Cutler, AJ, Marraffino, A, and Sikes, CR. "Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting." Journal of child and adolescent psychopharmacology 27.1 (February 2017): 66-74. Full Text
Lunsford-Avery, JR, Krystal, AD, and Kollins, SH. "Sleep disturbances in adolescents with ADHD: A systematic review and framework for future research." Clinical psychology review 50 (October 23, 2016): 159-174. Full Text
Schoenfelder, EN, and Kollins, SH. "Topical Review: ADHD and Health-Risk Behaviors: Toward Prevention and Health Promotion." Journal of pediatric psychology 41.7 (August 2016): 735-740. Full Text
Mitchell, JT, Sweitzer, MM, Tunno, AM, Kollins, SH, and McClernon, FJ. ""I Use Weed for My ADHD": A Qualitative Analysis of Online Forum Discussions on Cannabis Use and ADHD." PloS one 11.5 (January 2016): e0156614-. Full Text Open Access Copy
Faraone, SV, Childress, A, Wigal, SB, Kollins, SH, McDonnell, MA, DeSousa, NJ, and Sallee, FR. "Reliability and Validity of the Daily Parent Rating of Evening and Morning Behavior Scale, Revised." Journal of attention disorders (December 23, 2015).
Koblan, KS, Hopkins, SC, Sarma, K, Jin, F, Goldman, R, Kollins, SH, and Loebel, A. "Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults." Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 40.12 (November 2015): 2745-2752. Full Text
Vitiello, B, Lazzaretto, D, Yershova, K, Abikoff, H, Paykina, N, McCracken, JT, McGough, JJ, Kollins, SH, Greenhill, LL, Wigal, S, Wigal, T, and Riddle, MA. "Pharmacotherapy of the Preschool ADHD Treatment Study (PATS) Children Growing Up." Journal of the American Academy of Child and Adolescent Psychiatry 54.7 (July 2015): 550-556. Full Text
Childress, AC, Brams, M, Cutler, AJ, Kollins, SH, Northcutt, J, Padilla, A, and Turnbow, JM. "The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study." Journal of child and adolescent psychopharmacology 25.5 (June 2015): 402-414. Full Text
Mitchell, JT, Zylowska, L, and Kollins, SH. "Mindfulness Meditation Training for Attention-Deficit/Hyperactivity Disorder in Adulthood: Current Empirical Support, Treatment Overview, and Future Directions." Cognitive and behavioral practice 22.2 (May 2015): 172-191. Full Text
Mitchell, JT, and Kollins, SH. "ADHD in adolescence." Adolescent health psychology. Ed. W O'Donohue, L Benuto, and L Tolle. Springer, 2013. 423-445. (Chapter)
Kollins, SH. "Abuse potential of stimulant drugs used to treat ADHD." ADHD in Adults: Characterization, Diagnosis, and Treatment. January 1, 2011. 230-239. Full Text
Bidwell, LC, Garrett, ME, McClernon, FJ, Fuemmeler, BF, Williams, RB, Ashley-Koch, AE, and Kollins, SH. "Genotype and ADHD symptoms interact to predict adolescents' early smoking experiences in an epidemiological sample." November 2011.
Witt, KL, Shelby, MD, Itchon-Ramos, N, Faircloth, M, Kissling, GE, Chrisman, AK, Ravi, H, Murli, H, Mattison, DR, and Kollins, SH. "Chromosomal aberrations, sister chromatid exchanges, and micronuclei in lymphocytes of pediatric ADHD patients treated with stimulant drugs." August 2008.
Goodman, D, Adler, L, Kollins, SH, Weisler, R, Krishnan, S, Zhang, Y, and Biederman, J. "Efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder." July 2008.
Kollins, SH, Wigal, T, Vince, B, Lyne, A, and Farrand, K. "Cognitive and sedative effects of guanfacine extended release in children and adolescents aged 6 to 17 years with attention-deficit/hyperactivity disorder: Safety and sleep effects." April 1, 2008.
Sleep Dysfunction and Neurocognitive Outcomes in Adolescent ADHD awarded by National Institutes of Health (Mentor). 2016 to 2021
Targeting reward dysfunction as a mechanism to improve smoking cessation awarded by National Institutes of Health (Co-Mentor). 2016 to 2021
Effects of Nicotine Reduction on Smoking Behavior in ADHD Smokers awarded by National Institutes of Health (Principal Investigator). 2015 to 2020
Maternal obesity, child executive functions and child weight gain awarded by National Institutes of Health (Principal Investigator). 2015 to 2020
Smoking/Nicotine Dependence in Attention Deficit Hyperactivity Disorder (ADHD) awarded by National Institutes of Health (Principal Investigator). 2014 to 2019
Reactions to Reduced Nicotine Cigarettes in Young Adult Low-Frequency Smokers awarded by National Institutes of Health (Co Investigator). 2016 to 2019
Protecting Neurodevelopment in Latino Migrant Children by Reduced Exposure to Organophosphate Pesticides awarded by National Institutes of Health (Collaborator). 2017 to 2019
Increasing Motivation in ADHD Via Self-activation of VTA awarded by National Institutes of Health (Co-Principal Investigator). 2016 to 2018
Characterizing ADHD using a behavioral model of dopamine function awarded by Brain and Behavior Research Foundation (Mentor). 2016 to 2018
Rhodes EF004 awarded by Rhodes Pharmaceuticals L.P. (Principal Investigator). 2016 to 2017